UCL TECHNOLOGY FUND HAS APPROVED INVESTMENT OF UP TO £1M IN THE DEVELOPMENT OF A GENE THERAPY FOR (PERFORIN DEFICIENT) FAMILIAL HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

2018-06-12T10:53:39+00:00

The UCL Technology Fund (UCLTF) has approved an investment of up to £1m to support Professor Bobby Gaspar’s development of a gene therapy for (perforin deficien [...]

UCL TECHNOLOGY FUND HAS APPROVED INVESTMENT OF UP TO £1M IN THE DEVELOPMENT OF A GENE THERAPY FOR (PERFORIN DEFICIENT) FAMILIAL HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS2018-06-12T10:53:39+00:00

Autolus features in Fierce Biotech

2018-05-11T10:10:21+00:00

UCLB spinout, Autolus, features in a recent Fierce Biotech article, after filing to raise $100 million in a Nasdaq IPO. The clinical stage biopharmaceutical com [...]

Autolus features in Fierce Biotech2018-05-11T10:10:21+00:00

Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies

2018-04-24T12:35:49+00:00

- A CD19 CAR with novel targeting properties designed to reduce cytokine release syndrome – Autolus Limited, a clinical-stage biopharmaceutical company developi [...]

Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies2018-04-24T12:35:49+00:00

Intrinsic Features in EE News Europe

2018-03-15T16:23:47+00:00

Electronics industry publication, EE News Europe, features Intrinsic’s novel memristive RRAM devices, in a recent news article. The UCL spinout company of UCL E [...]

Intrinsic Features in EE News Europe2018-03-15T16:23:47+00:00

Intrinsic launches new website

2018-03-01T11:49:58+00:00

UCL spinout company, Intrinsic, launched its new website today. Intrinsic was established to commercialise the novel memristive RRAM devices developed by Prof T [...]

Intrinsic launches new website2018-03-01T11:49:58+00:00